期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

沙利度胺在血液病治疗中的应用 被引量：2

下载PDF
导出
摘要 沙利度胺（thalidomide）1953年在德国合成,20世纪50年代作为非巴比妥类催眠药广泛应用于妊娠期呕吐,因为有致畸作用而被禁用。到20世纪90年代随其具有抑制肿瘤坏死因子的活性、免疫调节和抗血管生成等作用的发现,又重新被广泛应用于治疗一些皮肤病、实体瘤和血液病如麻风病结节性红斑、前列腺癌、多发性骨髓瘤等。本文对其在血液病治疗的机制、应用作一综述。
作者 陈莉
机构地区 柳州市第三人民医院血液科
出处 《现代医药卫生》 2008年第6期865-867,共3页 Journal of Modern Medicine & Health
关键词 沙利度胺 血液病 治疗 非巴比妥类催眠药 肿瘤坏死因子 多发性骨髓瘤 抗血管生成 结节性红斑
分类号 R733.3 [医药卫生—肿瘤] R552 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献10

  • 1D'Amato RJ ,Loughnan MS,Flynn E,et al.Thalidomidl is an inhibitor of angiogenesis[J].Proc Natl Acad Sci USA, 1991,91:4082.
  • 2Verheul HM,Panigraphy D, Yuan J ,et al.Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits[J].Br J Cancer, 1999,79(1):114.
  • 3Fujita J. Thalidomide and its analogues inhibite lipopolysaahar-idemediated induction of cyclooxygensase-2[J].Clin Cancer Res, 2001,7 : 3349.
  • 4Moreira AL.Thalidomide exerta its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation[J].J Exp Med, 1993, 177:1675.
  • 5Dvies FE.Thalidomide and immunomodulatory derivatives aug-ment natural killer cell cytotoxicity in multiple myeloma[J]. Blood,2001, 98:210.
  • 6Mitsiades N.Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myrloma :Therapeutic implications[J].Blood, 2002,99:4525.
  • 7Rasa A, M E eye P, Dutt D,et al.Thalidom ide produces trantsfusion in fependence in long-standing refractory anemias of potientd with myelodysplastic syndromes[J].Blood ,2001,98(4):958.
  • 8Barosi G,Grossi A,Comotti B,et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasis [J].Br J Haematol, 2001,114(1):78.
  • 9王明琳,穆惠荣,刘曰芬,李英刚,吴红光,隋海涛.沙立度胺治疗急性白血病近期临床疗效观察[J].中华内科杂志,2003,42(5):296-299. 被引量：9
  • 10Fernandez LP,Schlegel PG,Baker J ,et al.Does thalidomide affect IL-2 response and produetion?[J].Exp Hematol, 1995,23(9) :978.

二级参考文献6

  • 1Singtml S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refiractory multiple myeloma. N Engl J Med, 1999,341 : 1565-1571.
  • 2Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol, 1994,87:503-508.
  • 3Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 1999,94:3717-3721.
  • 4Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia proenitor formation in myelodysplastic syndromes. Blood, 2001,97:1427-1434.
  • 5Aguayo A, Kantarjian H, Manshouri T, et al. Angiosenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 2000,96:2240-2245,2367-2644.
  • 6王全顺,周绮,于力,达万明,楼方定.环孢素A联合化疗方案治疗复发、难治性白血病[J].白血病．淋巴瘤,2002,11(1):18-20. 被引量：9

共引文献8

同被引文献22

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer Clin, 2007,57(1) :43-66.
  • 2Moreira A L, Sampaio E P, Zmuidzinas A. Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mR- NA degradation [J]. J ExpMed, 1993, 177(6): 1675-1680.
  • 3Keifer J A, Guttridge D C, Ashburner B P, et al. Inhibition of NF kappa B activity by thalidomide through suppression of I kappa B kinase activity[J]. J Biol Chem, 2001, 276 (25): 22383-22387.
  • 4Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade[J]. Immunopharmacology, 1996, 31(2-3): 213-221.
  • 5D'Amato R J, Loughnan M S, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis[J]. Proc Natl Acad Sei USA, 1994, 91(9) ;4082 -4085.
  • 6Kersi J M, Bex A, Mallo H, et al. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase Ⅱ study[J]. Cancer Immunol Immunother, 2005,54(9): 926-931.
  • 7Dmoszynska A, Podhorecka M, Manko J, et al. The influence of thalidomide therapy on cytokine secretion, immunopheno- type, BCL 2 expression and microvessel density in patients with resistant or relapsed multiple myeloma[J]. Neoplasm, 2005,52 (2):175- 181.
  • 8Richardson P, Hidershima T, Anderson K. Thalidomide: emerging role in cancer medicine[J]. Annu Rev Med, 2002, 53: 629- 657.
  • 9Desioze B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment[J]. Crit Rev Oncol Hematol, 2002,42 (3) :317- 325.
  • 10Matthews SJ,McCoy C.Thalidomide:a review of approved and investigational uses[J].Clin Ther,2003,25(2):342-395.

引证文献2

二级引证文献8

现代医药卫生
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部